The use of zoledronic acid in Japanese men with stage D2 prostate cancer

Nakamura,Kogenta; Yamada,Yoshiaki; Rosser,Charles J.; Arakawa,Maki; Zennmai,Kenji; Kato,Yoshiharu; Watanabe,Masahito; Katsuda,Remi; Tobiume,Motoi; Naruse,Katsuya; Aoki,Shigeyuki; Taki,Tomohiro; Saito,Hiroko; Hasegawa,Takaaki; Honda,Nobuaki

doi:10.3892/ol_00000002

The use of zoledronic acid in Japanese men with stage D2 prostate cancer

Authors:
- Kogenta Nakamura
- Yoshiaki Yamada
- Charles J. Rosser
- Maki Arakawa
- Kenji Zennmai
- Yoshiharu Kato
- Masahito Watanabe
- Remi Katsuda
- Motoi Tobiume
- Katsuya Naruse
- Shigeyuki Aoki
- Tomohiro Taki
- Hiroko Saito
- Takaaki Hasegawa
- Nobuaki Honda
View Affiliations

Affiliations: Department of Urology, Aichi Medical University School of Medicine, Aichi 480-1195, Japan. kogenaka@aichi-med-u.ac.jp
Published online on: January 1, 2010 https://doi.org/10.3892/ol_00000002
Pages: 13-16

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Zoledronic acid (ZOL) is a new generation bisphosphonate with improved efficacy benefits over pamidronate in preclinical testing. In addition, ZOL is superior to pamidronate in the treatment of hypercalcemia of malignancy. ZOL is also the first bisphosphonate to demonstrate efficacy in patients with bone metastases from solid tumors other than breast cancer, such as prostate cancer. In this study, we investigated ZOL treatment in 17 Japanese men with advanced prostate cancer, treated at the Aichi Medical University Hospital between August 2006 and November 2007. The 17 patients had biopsy-confirmed prostate cancer and were found to harbor bone metastasis upon bone scintigraphy. ZOL was administered intravenously at a dose of 4 mg over 15 min every 4 weeks. ZOL was well tolerated with mild renal dysfunction in 2 patients (11.8%), while 1 patient (5.8%) developed skin rash. No significant side effects were observed. Subjective improvement in bone pain was reported in 14 patients (32.4%). ZOL, therefore, is a safe and effective drug that remains an important component of the urologist's armamentarium against advanced prostate cancer.

View Figures

View References

1	Parkin DM, Laara E and Muir CS: Estimates of the worldwide frequency of sixteen major cancers in 1980. Int J Cancer. 41:184–197. 1988. View Article : Google Scholar : PubMed/NCBI
2	Parker SL, Tong T, Bolden S and Wingo PA: Cancer statistics. CA Cancer J Clin. 46:5–27. 1996.
3	Carlin BI and Andriole GL: The natural history, skeletal complications, and management of bone metastases in patients with prostate carcinoma. Cancer. 88:2989–2994. 2000. View Article : Google Scholar : PubMed/NCBI
4	Pentyala SN, Lee J, Hsieh K, Waltzer WC, Trocchia A, Musacchia L, et al: Prostate cancer: a comprehensive review. Med Oncol. 17:85–105. 2000. View Article : Google Scholar : PubMed/NCBI
5	Townsend MF, Sanders WH, Northway RO and Graham SD Jr: Bone fractures associated with luteinizing hormone-releasing hormone agonists used in the treatment of prostate carcinoma. Cancer. 79:545–550. 1997. View Article : Google Scholar : PubMed/NCBI
6	Collinson MP, Tyrell CJ and Hutton C: Osteoporosis occurring in two patients receiving LHRH analogs for carcinoma of the prostate (letter). Calcif Tissue Int. 54:327–328. 1994. View Article : Google Scholar : PubMed/NCBI
7	Daniell HW: Osteoporosis after orchiectomy for prostate cancer. J Urol. 157:439–444. 1997. View Article : Google Scholar : PubMed/NCBI
8	Clarke NW, McClure J and George NJ: The effects of orchiectomy on skeletal metabolism in metastatic prostate cancer. Scand J Urol Nephrol. 27:475–483. 1993. View Article : Google Scholar : PubMed/NCBI
9	Scher HI and Chung LW: Bone metastases: improving the therapeutic index. Semin Oncol. 21:630–656. 1994.PubMed/NCBI
10	Berruti A, Dogliotti L, Bitossi R, Fasolis G, Gorzegno G, Bellina M, et al: Incidence of skeletal complications in patients with bone metastatic prostate cancer and hormone refractory disease: predictive role of bone resorption and formation markers evaluated at baseline. J Urol. 164:1248–1253. 2000. View Article : Google Scholar
11	Major P, Lortholary A, Hon J, et al: Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. J Clin Oncol. 19:558–567. 2001.PubMed/NCBI
12	Rosen LS, Gordon D, Tchekmedyian S, et al: Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: A phase III, double-blind, randomized trial - The Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol. 21:3150–3157. 2003. View Article : Google Scholar
13	Saad F, Gleason DM, Murray R, et al: A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma: for the Zoledronic Acid Prostate Cancer Study Group. J Natl Cancer Inst. 94:1458–1468. 2002. View Article : Google Scholar
14	Green JR, Müller K and Jaeggi KA: Preclinical pharmacology of CGP 42′446, a new, potent, heterocyclic bisphosphonate compound. J Bone Miner Res. 9:745–751. 1994.PubMed/NCBI
15	Aapro M, Abrahamsson PA, Body JJ, et al: Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Ann Oncol. 19:420–432. 2008. View Article : Google Scholar : PubMed/NCBI
16	Vogel CL, Yanagihara RH, Wood AJ, et al: Safety and pain palliation of zoledronic acid in patients with breast cancer, prostate cancer, or multiple myeloma who previously received bisphosphonate therapy. Oncologist. 9:687–695. 2004. View Article : Google Scholar : PubMed/NCBI
17	Rosen LS, Gordon D, Antonio BS, et al: Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J. 7:377–387. 2001.
18	Saad F, Gleason DM, Murray R, et al: Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst. 96:879–882. 2004. View Article : Google Scholar
19	Saad F: Clinical benefit of zoledronic acid for the prevention of skeletal complications in advanced prostate cancer. Clin Prostate Cancer. 4:31–37. 2005. View Article : Google Scholar : PubMed/NCBI
20	Saad F: Bisphosphonates can prevent skeletal complications of malignant bone disease from prostate cancer and renal cell carcinoma. Eur Urol Suppl. 6:683–688. 2007. View Article : Google Scholar
21	Gulley JL, Wu S, Arlen PM and Dahut WL: Persistent hypocalcemia induced by zoledronic acid in a patient with androgen-independent prostate cancer and extensive bone metastases. Clin Genitourin Cancer. 5:403–405. 2007. View Article : Google Scholar : PubMed/NCBI
22	Bagan JV, Murillo J, Jimenez Y, et al: Vascular jaw osteonecrosis in association with cancer chemotherapy: series of 10 cases. J Oral Pathol Med. 34:120–123. 2005. View Article : Google Scholar : PubMed/NCBI
23	Vordos D, Paule B, Vacherot F, et al: Docetaxel and zoledronic acid in patients with metastatic hormone-refractory prostate cancer. BJU Int. 94:524–527. 2004. View Article : Google Scholar : PubMed/NCBI